Compare LINK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | ACRV |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 74.0M |
| IPO Year | 2007 | 2022 |
| Metric | LINK | ACRV |
|---|---|---|
| Price | $5.36 | $2.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.67 | ★ $11.67 |
| AVG Volume (30 Days) | 19.7K | ★ 259.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | N/A |
| Revenue This Year | $43.26 | N/A |
| Revenue Next Year | $19.16 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $2.66 | $1.27 |
| 52 Week High | $15.15 | $3.56 |
| Indicator | LINK | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 60.79 |
| Support Level | $3.57 | $2.07 |
| Resistance Level | $6.02 | $2.39 |
| Average True Range (ATR) | 0.35 | 0.14 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 20.33 | 96.43 |
Interlink Electronics Inc is a provider of sensing technologies and printed electronics solutions that enable Human-Machine Interface (HMI) devices and Internet-of-Things (IoT) applications. Its broad product and technology portfolio spans force and touch sensors, piezoelectric sensors, rugged HMI sensors, wearable and textile-based sensors and electrochemical gas and environmental sensors, along with instruments and fully integrated systems based on its sensor technologies. It serves blue-chip customers and emerging companies across diverse end-use markets, including medical, industrial, automotive, consumer electronics, wearables, environmental monitoring, and specialty applications. It operates in single segment: the design, development, and manufacture of sensor technologies.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.